The Analyst Landscape: 27 Takes On Biogen
The Analyst Landscape: 27 Takes On Biogen
分析師格局：27人對Biogen的看法
In the preceding three months, 27 analysts have released ratings for Biogen (NASDAQ:BIIB), presenting a wide array of perspectives from bullish to bearish.
在過去的三個月中，27位分析師發佈了Biogen（納斯達克股票代碼：BIIB）的評級，提出了從看漲到看跌的各種觀點。
The following table provides a quick overview of their recent ratings, highlighting the changing sentiments over the past 30 days and comparing them to the preceding months.
下表簡要概述了他們最近的評級，重點介紹了過去30天中情緒的變化，並將其與前幾個月進行了比較。
The 12-month price targets assessed by analysts reveal further insights, featuring an average target of $280.81, a high estimate of $364.00, and a low estimate of $200.00. Experiencing a 3.19% decline, the current average is now lower than the previous average price target of $290.05.
分析師評估的12個月目標股價揭示了進一步的見解，平均目標價爲280.81美元，最高估計爲364.00美元，低估值爲200.00美元。目前的平均價格下降了3.19％，現在低於之前的平均目標股價290.05美元。
Exploring Analyst Ratings: An In-Depth Overview
探索分析師評級：深入概述
The standing of Biogen...
通過對分...
登入免費觀看全文
登入/註冊
譯文內容由第三人軟體翻譯。
以上內容僅用作資訊或教育之目的，不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。